Organon & Co. Strategy and Business Model

Executive Overview

Organon is a global pharmaceutical company focused on women’s health, biosimilars, and a broad portfolio of established prescription medicines. Although Organon became an independent NYSE-listed company in June 2021 through the spin-off from Merck & Co., its roots trace back to the original Organon founded in 1923 in the Netherlands. Headquartered in Jersey City, New Jersey, Organon markets products in about 140 markets and is more internationally weighted than many U.S.-listed drug companies, with most sales generated outside the United States. Its best-known products include the Nexplanon/Implanon NXT long-acting contraceptive implant, fertility treatments such as Follistim AQ/Puregon, the Jada System for postpartum hemorrhage, and biosimilars including Hadlima. In FY2024, Organon generated approximately $6.4 billion of revenue. Strategically, Organon is not trying to outspend large innovative pharmaceutical companies in early-stage research. Instead, it uses cash flow from mature established brands to support dividends, debt reduction, biosimilar commercialization, and selective dealmaking intended to build a stronger, more durable women’s-health-led portfolio over time.

Organon at a Glance

Logo
Common name	Organon
Full legal name	Organon & Co.
Headquarters	Jersey City, New Jersey, United States
Ownership	Public company
Ticker	OGN
Exchange	NYSE - New York Stock Exchange
Market Cap	$3.53B
Revenue (FY2024)	#N/A
Founding / major historical milestones	Roots trace to 1923 in the Netherlands; became part of Schering-Plough in 2007; came under Merck & Co. through the 2009 Merck-Schering merger; spun off as an independent public company in 2021.
Industry or industries	Pharmaceuticals, women’s health, biosimilars, established prescription medicines
Key products or services	Women’s health medicines and devices, biosimilars, and a diversified portfolio of established prescription brands
Geographic footprint	Global; products marketed in about 140 markets, with revenue weighted toward markets outside the United States
Business segments as officially reported	One reportable segment; revenue is disclosed across three product categories: Women’s Health, Biosimilars, and Established Brands
Company website	https://www.organon.com

1. What Is the Strategy of Organon?

Using the Playing to Win framework, Organon’s strategy is best understood as a portfolio strategy: preserve and optimize cash flow from established medicines, reinvest selectively behind women’s health and biosimilars, and use disciplined business development to reshape the company toward areas where it believes it can build a more distinctive position.

1a. What is the winning aspiration of Organon?

Organon publicly frames its purpose as delivering impactful medicines and solutions for a healthier every day. In strategic terms, its winning aspiration is broader: to become a more focused and more valuable healthcare company, increasingly identified with women’s health, while still harvesting the economic value of a large established-brands portfolio. Winning for Organon does not mean competing head-to-head with the biggest research-based pharmaceutical companies on discovery science. It means generating durable cash flow, maintaining global relevance in mature brands, building a stronger women’s health franchise, and creating a biosimilars business with enough scale to matter financially.
1b. Where does Organon play?

Organon plays in three main areas disclosed in its reporting: Women’s Health, Biosimilars, and Established Brands. Within women’s health, it focuses on contraception, fertility, and maternal health. In biosimilars, it participates in selected biologic categories through partnerships rather than trying to build a fully independent biosimilar development engine from scratch. In established brands, it plays across multiple therapeutic areas and many countries where mature products can still retain meaningful demand, pricing, or brand equity. Geographically, Organon is notably international, with a large part of its business outside the United States, including markets where its legacy portfolio remains commercially attractive.
1c. How does Organon plan to win?

Organon’s plan to win rests on combining several advantages that are individually modest but collectively useful. First, it uses the cash generation of its established brands to fund dividends, debt reduction, and targeted growth investments. Second, it focuses on women’s health areas where specialist relationships, clinical education, and market access matter, rather than trying to be a broad primary-care giant. Third, it uses a partnership-oriented model in biosimilars, relying on external development and manufacturing capabilities while contributing commercialization, market access, and global reach. Fourth, it uses business development to add assets that fit its portfolio, especially in women’s health. The underlying logic is that careful portfolio curation and operational discipline can create more value than a high-risk, high-burn innovation model.
1d. What capabilities must Organon have in place?

To execute this strategy, Organon needs strong capabilities in global regulatory management, pharmacovigilance, quality systems, and supply reliability across many markets. It also needs portfolio management discipline for mature brands, payer and tender-management capabilities for biosimilars, and specialist commercial execution in women’s health. Business development is another essential capability because Organon’s growth plan depends in part on licensing and acquisitions rather than only on internally discovered products. Finally, it needs the ability to integrate acquired or in-licensed assets into its commercial and operational network without adding disproportionate overhead.
1e. What management systems does Organon require?

Organon needs management systems that reinforce capital discipline and portfolio accountability. That includes franchise-level performance tracking, country-level pricing and reimbursement management, launch-governance processes, and strong compliance and quality oversight. Because the company carries meaningful leverage relative to its size, capital-allocation systems are especially important: management has to decide how much cash goes to debt reduction, dividends, internal investment, and dealmaking. Organon also needs robust demand-planning and supply-management systems because stockouts or quality problems can quickly undermine mature brands, specialist products, and biosimilar access wins.

2. What Are the Current Strategic Initiatives of Organon?

Based on Organon’s FY2024 disclosures and recent management commentary, the company’s current strategic initiatives are concentrated in a few clear areas.

Expand the women’s health franchise. Organon continues to invest behind its women’s health portfolio, with Nexplanon as the flagship asset, fertility products as a durable specialist category, and maternal-health offerings such as the Jada System as newer growth vectors. This initiative is about both protecting existing franchises and broadening the company’s relevance across the female health journey.
Scale biosimilars, especially where market access can unlock volume. Biosimilars remain a strategic growth area even if they are not yet the company’s largest revenue contributor. Organon has emphasized commercial execution, formulary access, contracting, and broader uptake of key biosimilars such as Hadlima, while also supporting an external development pipeline through partnerships.
Optimize the established-brands portfolio for cash generation. Organon’s established brands remain the economic engine of the company. Management’s task is not simply to harvest decline passively; it is to manage pricing, supply continuity, local promotion, distributor relationships, and portfolio mix so these assets generate as much durable cash as possible for as long as possible.
Use business development to reshape the portfolio. Organon has repeatedly signaled that acquisitions, licenses, and collaborations are important tools, particularly in women’s health and adjacent categories that fit its commercial infrastructure. This is a core part of its strategy, not a side activity.
Maintain financial discipline while investing selectively. Since becoming independent, Organon has had to balance growth ambitions against a leveraged balance sheet. Debt reduction, dividend support, and disciplined investment have therefore become strategic initiatives in their own right.

3. What Is the Business Model of Organon?

Organon’s business model is the sale of branded prescription medicines, biosimilars, and selected medical-device-related solutions through global pharmaceutical channels. Customers do not buy a subscription or a software license; they buy products that are prescribed, reordered, reimbursed, tendered, stocked, and replenished.

What customers actually buy: healthcare systems, wholesalers, pharmacies, hospitals, and providers buy finished pharmaceutical products and, in some cases, device-based solutions such as Jada. The end users are patients, but the economic buyers are often wholesalers, hospital systems, government tenders, managed-care organizations, and specialty providers.

Recurring versus one-time: the model is not contractually recurring in a software sense, but much of it is repeat-driven. Chronic and long-tail therapies are reordered. Fertility treatments are purchased across treatment cycles. Biosimilars depend on ongoing account access and reorder behavior. Established brands can persist for years in markets where physician familiarity and reimbursement remain intact.

Pricing power: pricing power is mixed. Organon generally has more room to protect value in certain differentiated women’s health products and in markets where established brands retain local brand equity. Pricing power is weaker in biosimilars, where payer negotiations, tenders, and incumbent biologic competition are central. In the United States, rebates and formulary dynamics also constrain realized pricing.

Why the business mix matters: Organon’s mix is strategically important because the company’s largest revenue bucket, Established Brands, is also the most structurally exposed to erosion over time. Women’s Health and Biosimilars are smaller but are more important to long-term growth and valuation. In effect, Organon is trying to turn cash-rich mature products into funding for more durable growth platforms.

What drives margins and cash generation: gross margin is influenced by product mix, manufacturing route, royalty and partnership economics, and the intensity of price competition. Biosimilars can carry lower economic margins than proprietary brands because of pricing pressure and partner-sharing arrangements. Operating margin depends heavily on sales-force efficiency, launch spending, SG&A discipline, and the cost of supporting a global regulatory and quality infrastructure. Cash generation benefits from the fact that Organon’s R&D model is more selective than that of big research pharma, but debt service and working-capital management remain important uses of cash.

4. What Products and/or Services Does Organon Sell?

Organon sells a mix of pharmaceutical products and selected healthcare solutions organized around three reported product categories.

Women’s Health. This category includes contraception, fertility, and maternal-health products. The best-known brand is Nexplanon/Implanon NXT, a long-acting reversible contraceptive implant. Organon also sells fertility therapies such as Follistim AQ/Puregon and has expanded into maternal-health solutions through the Jada System. This franchise is strategically important because it is where Organon is trying most clearly to differentiate itself.
Biosimilars. Organon markets biosimilars in immunology and oncology categories through partnerships. Publicly visible products include Hadlima, Renflexis, and Ontruzant in relevant markets. Biosimilars are important less for near-term scale alone and more because they give Organon participation in large biologic categories without taking full originator-style R&D risk.
Established Brands. This is a broad portfolio of mature prescription medicines across multiple therapeutic areas, including categories such as cardiovascular, respiratory, dermatology, pain, and other primary-care and specialty uses. These products are the largest contributor to revenue and cash flow, even though they are not the main long-term growth story.

As of FY2024, Established Brands remained the largest revenue contributor, while Women’s Health was the clearest strategic growth priority and Biosimilars remained an important platform for future expansion.

5. What Are the Key Competitors or Peers of Organon?

Organon does not have a single clean peer set because it competes differently in women’s health, biosimilars, and mature brands. The most relevant competitors and comparables include the following:

Bayer. A major competitor in women’s health, especially contraception and related specialist categories.
Viatris. One of the closest business-model comparables because of its large off-patent and globally distributed portfolio.
Sandoz. A leading biosimilars and generics company that competes directly in off-patent and biologic follow-on markets.
Teva. A major generics player whose products can substitute for some mature branded medicines.
Celltrion. A significant biosimilars competitor in immunology and oncology, particularly in hospital and payer-driven channels.
Pfizer. Not a perfect match, but a large pharmaceutical competitor with overlapping hospital, specialty, and international channels in some categories.
Gedeon Richter. A notable women’s-health-focused pharmaceutical peer, especially in Europe and certain international markets.
Ferring Pharmaceuticals. A reproductive-health and fertility competitor with strength in specialist women’s health categories.
AbbVie. In biosimilars, incumbent originator companies such as AbbVie remain important competitors because the reference biologic still shapes access, pricing, and switching behavior.
CooperSurgical. A peer in fertility and reproductive-health solutions, particularly where devices, procedures, and specialist-provider relationships matter.

Competition varies substantially by country, molecule, channel, and reimbursement regime. In some markets Organon competes primarily against generics; in others it competes against originator biologics, local brands, or specialist women’s health franchises.

6. What Is the Marketing Strategy of Organon?

Organon does not market like a consumer packaged goods company. Its marketing strategy is primarily a healthcare-professional, medical-affairs, and market-access model tailored to product type.

In women’s health, marketing appears to rely heavily on physician education, specialist outreach, patient-awareness support where appropriate, and practical adoption tools. Products such as Nexplanon and Jada require more than branding; they require training, clinical confidence, and workflow fit. That makes field education and provider support important.

In biosimilars, marketing is more account-based and evidence-driven. Success depends on formulary access, hospital-system adoption, payer contracting, and confidence in interchangeability, supply, and total cost of care. This is closer to institutional selling than classic brand advertising.

In Established Brands, marketing is typically more selective and efficiency-oriented. The goal is usually to preserve demand and share where the economics justify support, rather than to fund large promotional campaigns. Overall, marketing is an important enabling capability for Organon, but it is not the primary differentiator by itself; the company’s edge comes more from portfolio fit, commercial execution, and international channel management.

7. What Are the Key Customer Segments of Organon?

Organon serves several distinct customer groups, and the balance matters because each requires a different commercial approach.

Pharmaceutical wholesalers and specialty distributors. In large markets, especially the United States, a significant share of product flow goes through major wholesalers and distributors that supply pharmacies, hospitals, and providers.
Obstetricians, gynecologists, and family-planning providers. These are core prescribers and procedure-oriented users for contraception and maternal-health products.
Fertility clinics and reproductive endocrinologists. These specialist customers matter for Organon’s fertility portfolio and often require high-touch clinical support.
Hospitals, infusion centers, and health systems. These are important for biosimilars and certain institutional products where formulary decisions and procurement contracts drive demand.
Government agencies and national health systems. In many markets outside the United States, tender systems and public reimbursement bodies are central customers in practice.
Retail pharmacies and managed-care intermediaries. Pharmacies dispense many of Organon’s products, while pharmacy benefit managers and payers strongly influence access and net pricing in the United States.

Organon is diversified across multiple end markets, but it is especially exposed to specialist women’s health channels, public-health systems outside the United States, and concentrated pharmaceutical distribution channels.

8. What Is the Sales Model of Organon?

Organon uses a hybrid pharmaceutical sales model. In larger markets it sells through direct commercial organizations, while in smaller or more fragmented markets it also relies on local distributors and channel partners. Products reach end customers through wholesalers, retail and specialty pharmacies, hospitals, clinics, fertility centers, and government procurement systems.

The field model is not uniform across the portfolio. Women’s health often requires specialist representatives and clinical support calling on obstetricians, gynecologists, and fertility providers. Biosimilars rely more on key-account management, hospital and payer access work, and contracting. Established brands generally need a more selective and cost-conscious model that varies by country and product economics.

This channel structure affects growth and pricing in important ways. Organon can benefit from its broad international footprint, but it also faces local reimbursement rules, tender cycles, distributor concentration, and country-by-country pricing complexity. For consultants, this kind of go-to-market structure often creates opportunities in sales-force design, account segmentation, tender excellence, pricing analytics, and distributor strategy.

9. In What Geographies Does Organon Operate?

Organon operates globally and is unusually international for a U.S.-listed pharmaceutical company. As of FY2024, most of its revenue came from outside the United States. That matters because many of its established brands and several women’s health products have stronger or more durable positions internationally than they do in the U.S. market.

The company serves markets across North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. Its headquarters are in Jersey City, New Jersey, but its heritage and operational footprint include longstanding European roots. Organon’s manufacturing and supply network spans company facilities, former Merck-related infrastructure, external manufacturing partners, and regional distribution networks.

Geographic breadth is a strategic asset, but it also increases complexity. Organon must manage different reimbursement systems, country-specific product lifecycles, local regulatory requirements, and foreign-exchange exposure. The company is not concentrated in one domestic market; its economics depend on being able to operate a truly multinational pharmaceutical portfolio.

10. Who Are the Owners of Organon?

Organon is a publicly traded company listed on the New York Stock Exchange. As of Organon’s 2025 proxy materials and other public ownership filings available in early 2025, the company did not have a controlling shareholder. Its shareholder base was primarily institutional, with large asset managers such as The Vanguard Group, BlackRock, and State Street among the largest disclosed holders.

11. How Is Organon Organized?

Organon is organized as a public holding company with operating subsidiaries around the world. From a reporting standpoint, it has one reportable segment, but management and investors typically understand the business through three product categories: Women’s Health, Biosimilars, and Established Brands.

Practically, the company appears to combine centralized functions with local market execution. Core functions such as finance, legal, regulatory, quality, supply, and business development are managed centrally, while country organizations handle local commercialization, pricing, reimbursement, distributor management, and market access. This is a common structure for global pharmaceutical companies with many country-specific product economics.

The result is an organization that is simpler than a diversified big-pharma conglomerate but still complex because of its geographic spread and broad long-tail portfolio.

12. How Does Organon Operate?

On a day-to-day basis, Organon operates as a global pharmaceutical portfolio manager and commercial operator. It develops, licenses, manufactures, sources, registers, markets, and distributes medicines and selected healthcare solutions across many countries.

Portfolio sourcing and development. Organon combines internal development work with external partnerships, licenses, and acquisitions.
Regulatory and quality management. The company must maintain approvals, label compliance, pharmacovigilance, and product quality across many jurisdictions.
Manufacturing and supply. Products are produced through a mix of internal capabilities, partners, and third-party manufacturing arrangements.
Commercial execution. Local teams manage wholesalers, hospitals, government tenders, specialists, and reimbursement channels.
Lifecycle management. Mature products require ongoing pricing, supply, promotion, and portfolio decisions to maximize cash generation.

Operational complexity comes from the breadth of the portfolio. A company focused on one or two breakthrough products can concentrate resources. Organon instead has to manage specialist women’s health products, price-sensitive biosimilars, and a wide array of mature brands across many countries. Reliability, compliance, and portfolio discipline therefore matter as much as breakthrough innovation.

13. What Are the Growth Opportunities for Organon?

The most plausible growth opportunities for Organon are visible from its portfolio and public strategy.

Deepening women’s health. Organon has room to grow through broader adoption of Nexplanon, expansion of fertility offerings, greater uptake of Jada, and the addition of further women’s health assets through deals.
Expanding biosimilars. Biosimilars remain a meaningful long-term opportunity as healthcare systems seek lower-cost biologic options. Organon’s challenge is to translate pipeline access and formulary wins into durable volume.
Using its international footprint better. Organon’s large ex-U.S. commercial network can support launches and acquired assets that would be harder for smaller specialty companies to scale globally.
Portfolio reshaping through business development. Targeted acquisitions, licenses, and collaborations can improve Organon’s mix faster than waiting for internal development alone.
Operational improvement in Established Brands. Better pricing, channel management, SKU rationalization, and supply reliability can stabilize cash flows and fund growth investments.
Selective adjacent categories. Organon may have room to expand in areas adjacent to women’s health where specialist overlap, provider relationships, or care-pathway relevance already exist.

The main constraints are clear as well: ongoing erosion of mature brands, payer pressure in biosimilars, execution risk in new launches, regulatory delays, supply complexity, and the need to balance growth spending against leverage and shareholder returns.

14. What Is the History of Organon?

Organon’s roots date to 1923 in Oss, the Netherlands, where the original Organon was established. Over time, the Organon name became associated with women’s health and hormone-related medicines, and the business changed hands through several large-corporate ownership structures.

A major turning point came in 2007, when Schering-Plough acquired Organon BioSciences. Another followed in 2009, when Merck & Co. completed its merger with Schering-Plough, bringing the Organon assets into Merck’s portfolio. For more than a decade, those products sat inside a much larger pharmaceutical organization.

The modern Organon was created when Merck spun off the business as Organon & Co. in June 2021. That spin gave Organon a standalone balance sheet, its own capital-allocation decisions, and a clearer strategic identity around women’s health, biosimilars, and established brands. After independence, Organon moved quickly to supplement its portfolio with targeted deals, including Alydia Health and Forendo Pharma, both aimed at strengthening the women’s health platform.

15. What Are the Key Suppliers to Organon?

Suppliers matter strategically for Organon because product availability, quality, and cost discipline are central to a portfolio that spans biologics, devices, and mature small-molecule brands. Organon does not publicly publish a full ranked supplier list, but several supplier categories and named counterparties stand out.

Merck-related supply arrangements. Following the 2021 spin, Merck remained an important counterparty for certain separation-related manufacturing and supply activities. Even as those arrangements evolve over time, the transition away from inherited infrastructure has been strategically important.
Samsung Bioepis. This relationship is especially important in biosimilars, where development and manufacturing partnership economics shape Organon’s ability to commercialize products such as Hadlima and other biosimilar assets.
Active pharmaceutical ingredient and finished-dose manufacturers. Organon relies on a network of suppliers and contract manufacturers for core pharmaceutical inputs and production.
Device and component suppliers. Women’s health products that involve delivery systems or devices require specialized components and strict quality control.
Packaging, cold-chain, and logistics providers. Global pharmaceutical distribution depends on serialization, temperature control where required, and reliable in-market delivery.

Supplier structure matters because Organon’s strategy depends on dependable cash generation. A supply disruption does not just delay revenue; it can weaken tenders, physician confidence, and the economics of a mature brand with little room for error.

16. What Are the Key Brands Owned by Organon?

At Organon, branding matters more at the product level than at the corporate master-brand level. Physician trust, reimbursement familiarity, and local product recognition are often more important than broad consumer advertising.

Nexplanon / Implanon NXT. Organon’s flagship women’s health brand and one of its most strategically important products, centered on long-acting reversible contraception.
Follistim AQ / Puregon. Key fertility brands that anchor Organon’s reproductive-medicine presence with specialist providers.
Jada System. A maternal-health device-based solution that broadens Organon’s women’s health identity beyond pharmaceuticals.
Hadlima. A major biosimilar brand and an important indicator of Organon’s ability to compete in payer- and access-driven biologics markets.
Renflexis. A biosimilar brand that supports Organon’s broader immunology and institutional-care presence.
Ontruzant. An oncology biosimilar that expands Organon’s footprint in hospital and specialty channels.
Established local brands. Many of Organon’s mature medicines are more important in local or regional markets than as global household names. Their value lies in prescriber familiarity, installed demand, and distribution reach.

17. How Does the Supply Chain of Organon Function?

Organon’s supply chain is a hybrid pharmaceutical network that combines internal production, legacy infrastructure, third-party manufacturers, external development partners, packaging operations, and regional distribution channels. The exact flow differs by product type.

For small-molecule established brands, the supply chain typically starts with active ingredient sourcing and finished-dose manufacturing, followed by packaging, local regulatory release, and shipment into wholesalers, pharmacies, and tender systems. For biosimilars, the supply chain is more biologics-oriented and can include partner-developed drug substance, fill-finish, cold-chain handling, and institution-focused distribution. For women’s health devices or delivery-system-based products, component quality and assembly control become especially important.

Supply-chain reliability is strategically important because Organon cannot afford avoidable revenue leakage. Mature brands may be easy for customers to replace if stock is unavailable. Biosimilar contracts can be lost if service levels disappoint. Specialist women’s health products depend on provider confidence and continuity. That makes forecasting, inventory discipline, dual-sourcing where feasible, and quality management central operating priorities.

18. What Are the Key Assets of Organon?

Organon is not asset-light in the way a pure software company is, but its most important assets are not only physical plants. In pharmaceuticals, regulated intangible assets are often more valuable than bricks and mortar.

Product rights and marketing authorizations. The company’s ability to sell medicines across many countries depends on licenses, registrations, and regulatory dossiers.
The women’s health franchise. Nexplanon, fertility products, maternal-health offerings, and related specialist relationships are among Organon’s most strategically valuable assets.
The established-brands portfolio. This long-tail portfolio is the company’s main cash-generation engine.
Biosimilar commercialization rights and partnerships. These assets give Organon access to large therapeutic markets without fully replicating the infrastructure of an originator biologics company.
Global commercial infrastructure. Organon’s ability to commercialize products across about 140 markets is itself an asset, especially for in-licensed or acquired products.
Manufacturing, quality, and supply capabilities. Whether internal or partner-based, these capabilities are essential barriers to failure in a regulated industry.

For Organon, asset intensity shows up in regulatory complexity, product rights, and global commercialization capabilities as much as in physical manufacturing sites.

19. What Is the R&D Strategy of Organon?

Organon’s R&D strategy is more selective than that of a traditional large-cap innovation-led pharmaceutical company. The company has not positioned itself as a broad discovery platform with a massive early-stage pipeline. Instead, its approach appears to emphasize focused internal development, lifecycle management, and external innovation sourcing.

In women’s health, R&D is directed toward differentiated needs where Organon believes specialist knowledge and commercial fit matter. In biosimilars, much of the heavy scientific and manufacturing development work is done through partners, with Organon contributing commercialization and portfolio economics. In established brands, innovation is less about breakthrough discovery and more about sustaining value through lifecycle management, formulation support, market expansion, and operational continuity.

That means Organon’s innovation model is closely tied to business development. Acquisitions and licenses are not separate from R&D strategy; they are part of how the company accesses innovation without carrying the full cost structure of a discovery-heavy model.

20. What Is the Finance Strategy of Organon?

Organon’s finance strategy has been shaped by the fact that it became independent with meaningful leverage. As a result, capital allocation is central to the equity story. The company’s financial logic is to use cash flow from established brands and other commercial products to support four priorities: maintain liquidity, reduce leverage over time, fund the dividend, and invest selectively in growth through launches and business development.

This has several implications. First, debt reduction matters strategically because it increases flexibility. Second, Organon has to be disciplined about dealmaking; not every attractive asset can be pursued if it strains the balance sheet. Third, operating execution and working-capital management matter more than they might at a high-growth biotech, because cash conversion helps finance both shareholder returns and reinvestment.

Organon’s finance strategy therefore supports its broader corporate strategy by turning a mature portfolio into investable cash while avoiding the need for outsized equity dilution or overly aggressive balance-sheet risk.

21. What Major Acquisitions Has Organon Made?

Acquisitions have been important to Organon’s strategy, but the company’s pattern has been targeted rather than transformational. Since becoming independent, Organon has used bolt-on acquisitions and partnerships to strengthen women’s health and expand the pipeline.

Alydia Health (2021). This acquisition added the Jada System, a device-based treatment for postpartum hemorrhage, and broadened Organon’s reach in maternal health.
Forendo Pharma (2021). This deal added development-stage women’s health assets and reflected Organon’s willingness to buy pipeline, not just commercial products, where the fit is strong.

Just as important, Organon has relied heavily on collaborations and licensing arrangements, especially in biosimilars, where partnerships can provide a more capital-efficient route into new markets than outright acquisitions. In other words, M&A is part of Organon’s portfolio-building toolkit, but not the only one.

22. How Companies Like Organon Leverage Independent Consultants through Umbrex

Umbrex has built a global community of more than 8,000 independent management consultants based in more than 50 countries, including alumni of McKinsey, Bain, BCG, and other top consulting firms. Companies like Organon engage Umbrex when they need talent with the training those firms provide, but they do not need a full consulting team with all the overhead. Umbrex consultants work across strategy, operations, organization, marketing, sales, finance, technology, ERP, and AI, which fits well with the mix of portfolio, market-access, supply-chain, and transformation issues that matter to Organon.

Women’s health growth strategy. Build a country-by-country growth plan for Nexplanon, fertility, and maternal-health assets, including segment prioritization and launch sequencing.
Biosimilar access and contracting strategy. Support pricing, rebate, tender, and account strategy for products such as Hadlima and future biosimilar launches.
Established-brands portfolio optimization. Identify which brands to defend, which to harvest, and which to rationalize based on country economics, channel structure, and supply complexity.
Commercial due diligence for licenses and acquisitions. Screen women’s health and specialty-health targets, estimate market potential, and assess strategic fit before a deal is signed.
Post-merger integration. Help integrate bolt-on acquisitions such as women’s health devices or specialty brands into Organon’s operating model, salesforce, and support functions.
Sales-force effectiveness. Redesign territories, account coverage, and incentive structures for obstetricians, gynecologists, fertility specialists, hospitals, and key accounts.
Supply-chain resilience and procurement transformation. Reduce single-source risk, improve contract manufacturing oversight, and lower external spend across packaging, logistics, and production categories.
Working-capital and inventory improvement. Improve sales and operations planning, demand forecasting, and inventory deployment across a broad multinational portfolio.
Global pricing and market-access analytics. Build tools and processes to manage tender pricing, payer negotiations, net-price visibility, and country-level profitability.
ERP, data, and AI-enabled decision support. Deploy practical analytics for product profitability, demand planning, portfolio management, and management reporting without launching a large-scale consulting program.

Organon Strategy and Business Model